Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction

American Heart Journal

Volumn 165, Issue 4, 2013, Pages 537-543

  Mehilli, Julinda ^a   Neumann, Franz Josef ^b,d   Ndrepepa, Gjin ^b   King, Lamin ^b   Schulz, Stefanie ^b   Maimer Rodrigues Da Cunha, Fatima ^b   Jochheim, David ^a   Byrne, Robert A ^c   Hausleiter, Jörg ^a   Ott, Ilka ^c   Massberg, Steffen ^a   Kastrati, Adnan ^b   Pache, Jürgen ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; HEPARIN; HIRULOG;

AGED; ARTICLE; BLEEDING; BLOOD VESSEL PARAMETERS; DEATH; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RECURRENT DISEASE; SEX DIFFERENCE; TARGET VESSEL REVACULARIZATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANTIBODIES, MONOCLONAL; ANTITHROMBINS; FEMALE; HIRUDINS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; RECOMBINANT PROTEINS; SEX FACTORS; THROMBOLYTIC THERAPY;

EID: 84875437286     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.12.021     Document Type: Article

References (29)

1. E.S. Ford, U.A. Ajani, and J.B. Croft Explaining the decrease in U.S. deaths from coronary disease, 1980-2000 N Eng J Med 356 23 2007 2388 2398
2. A.J. Lansky, R. Mehran, and E. Cristea Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial) Am J Cardiol 103 9 2009 1196 1203
3. J. Mehilli, A. Kastrati, and J. Dirschinger Sex-based analysis of outcome in patients with acute myocardial infarction treated predominantly with percutaneous coronary intervention JAMA 287 2 2002 210 215
4. A.H. Al-Fiadh, N. Andrianopoulos, and O. Farouque Contemporary outcomes in women undergoing percutaneous coronary intervention for acute coronary syndromes Int J Cardiol 151 2 2011 195 199
5. S. Setoguchi, D.H. Solomon, and R. Levin Gender differences in the management and prognosis of myocardial infarction among patients > or = 65 years of age Am J Cardiol 101 11 2008 1531 1536
6. J. Mehilli, G. Ndrepepa, and A. Kastrati Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction J Am Coll Cardiol 45 6 2005 828 831
7. A.K. Jacobs Coronary intervention in 2009: are women no different than men? Circ Cardiovasc Interv 2 1 2009 69 78
8. R.D. Anderson, and C.J. Pepine Gender differences in the treatment for acute myocardial infarction: bias or biology? Circulation 115 7 2007 823 826
9. K.P. Alexander, A.Y. Chen, and L.K. Newby Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative Circulation 114 13 2006 1380 1387
10. R. Mehran, S. Pocock, and E. Nikolsky Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials JACC Cardiovasc Interv 4 6 2011 654 664
11. G. Ndrepepa, S. Schulz, and D. Keta Bleeding after percutaneous coronary intervention with bivalirudin or unfractionated heparin and one-year mortality Am J Cardiol 105 2 2010 163 167
12. G.W. Stone, B. Witzenbichler, and G. Guagliumi Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial Lancet 377 9784 2011 2193 2204
13. A. Kastrati, F.J. Neumann, and S. Schulz Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction N Eng J Med 365 21 2011 1980 1989
14. A. Kastrati, J. Mehilli, and F.J. Neumann Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial JAMA 295 13 2006 1531 1538
15. S.D. Wiviott, E. Braunwald, and C.H. McCabe Prasugrel versus clopidogrel in patients with acute coronary syndromes N Eng J Med 357 20 2007 2001 2015
16. J. Mehilli, G. Ndrepepa, and A. Kastrati Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial Am Heart J 154 1 2007 158e1 158e7
17. J.B. Schwartz The influence of sex on pharmacokinetics Clin Pharmacokinet 42 2 2003 107 121
18. E. Boersma, R.A. Harrington, and D.J. Moliterno Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials Lancet 359 9302 2002 189 198
19. S.S. Anand, C.C. Xie, and S. Mehta Differences in the management and prognosis of women and men who suffer from acute coronary syndromes J Am Coll Cardiol 46 10 2005 1845 1851
20. G. Ndrepepa, T. Schuster, and M. Hadamitzky Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention Circulation 125 11 2012 1424 1431
21. R. Robson, H. White, and P. Aylward Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender Clin Pharmacol Ther 71 6 2002 433 439
22. G. Ndrepepa, A. Kastrati, and J. Mehilli Age-dependent effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions Circulation 114 19 2006 2040 2046
23. W. Hochholzer, S.D. Wiviott, and E.M. Antman Predictors of bleeding and time dependence of association of bleeding with mortality: insights from the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel - Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) Circulation 123 23 2011 2681 2689
24. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 23 2011 2736 2747
25. K. Tsujita, E. Nikolsky, and A.J. Lansky Impact of anemia on clinical outcomes of patients with ST-segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS-AMI trial) Am J Cardiol 105 10 2010 1385 1394
26. M. Chacko, A.M. Lincoff, and K.E. Wolski Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial Am Heart J 151 5 2006 1032e1 1032e7
27. V. Rajagopal, A.M. Lincoff, and D.J. Cohen Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial Am Heart J 152 1 2006 149 154
28. C. Pristipino, F. Pelliccia, and A. Granatelli Comparison of access-related bleeding complications in women versus men undergoing percutaneous coronary catheterization using the radial versus femoral artery Am J Cardiol 99 9 2007 1216 1221
29. Authors/Task Force M, P.G. Steg, and S.K. James ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J 33 20 2012 2569 2619